About The Study: This scoping review determined that although artificial intelligence (AI) dermatology mobile apps hold promise for improving access to care and patient outcomes, in their current state, they may pose harm due to potential risks, lack of consistent validation, and misleading user communication. Addressing challenges in efficacy, safety, and transparency through effective regulation, validation, and standardized evaluation criteria is essential to harness the benefits of these apps while minimizing risks.
Authors: Veronica Rotemberg, M.D., Ph.D., of Memorial Sloan Kettering Cancer Center in New York, and Associate Editor, JAMA Dermatology, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamadermatol.2024.0468)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This article is being released to coincide with presentation at the 2024 American Academy of Dermatology Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.0468?guestAccessKey=fcd7d1aa-de4b-451c-86e3-0b77d90f97d9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030724
JAMA Dermatology